TABLE 2.
Observed clinical symptoms in included dogs with nDLBCL
| Clinical sign | Substage B (n = 40, 71%) | B‐symptoms (n = 20, 36%) |
|---|---|---|
| Lymphadenopathy (n = 55, 100%) | − | − |
| Lethargy (n = 35, 64%) | + | − |
| Behavioural changes (n = 18, 33%) | + | − |
| Weakness (n = 14, 25%) | + | − |
| Hyporexia (n = 13, 24%) | + | − |
| Weight loss (n = 13, 24%) | + | + |
| Diarrhoea (n = 9, 16%) | + | − |
| Tachypnea in rest (n = 9, 16%) | + | + |
| Fever (n = 8, 15%) | + | + |
| Coughing (n = 8, 15%) | + | − |
| Sneezing (n = 7, 13%) | + | − |
| Ocular changes (n = 6, 11%) | + | − |
| Choke (n = 6, 11%) | + | − |
| Dyspnoe (n = 5, 9%) | + | − |
| Vomiting (n = 5, 9%) | + | − |
| Nasal discharge (n = 5, 9%) | + | − |
| Polyuria/polydipsia (n = 4, 7%) | + | − |
| Bruising (n = 3, 5%) | + | − |
Note: −, absence of substage B and/or B‐symptoms; +, presence substage B and/or B‐symptoms; Substage B, presence of any clinical sign but lymphadenopathy; clinical signs in bold show a presence of B‐symptoms; n, number of patients.